



#18

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Johannes C. van Groeninghen

Serial No.: 09/446,996

Filed: December 30, 1999

For: METHOD FOR RECOGNIZING AND DETERMINING GNRH RECEPTORS AND THE USE OF GNRH AGONIST FOR DECREASING THE REPLICATION OF MALIGNANT CELLS BEARING GNRH RECEPTORS OF TUMORS ORIGINATING IN THE BRAIN AND/OR NERVOUS SYSTEM AND/OR MENINGES AND/OR OF KAPOSI SARCOMA

Confirmation No.: 3246

Examiner: J. Andres

Group Art Unit: 1646

Attorney Docket No.: 2183.02-5649US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL994843427USDate of Deposit with USPS: August 17, 2005Person making Deposit: Steve Wong

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of U.S. patents are not being submitted pursuant to M.P.E.P. 609 III A(2). Copies of non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 6,214,969	04-2001	Janaky et al.

Other Documents

HE et al., 1986, Clinical Chemistry, Vol. 32, No. 6, pp. 1159, abstract #542.

HOITINK et al., Stability of Gonadorelin and Relation Compounds, dissertation, U of Utrecht, 8/6/1998, CH. 1, p. 15, para. 2.

LAUE et al., Amer. J. of Diseases of Children, 1985, vol. 139, no. 11, pp. 1097-1100.

LIMONTA et al., The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans, Front, Neuroendocrinol. 203, pp. 279-95, Vol. 24.

MORETTI et al., Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells, J. of Clin. Endocrin. & Metab., 2002, pp. 3791-97, Vol. 87, No. 8.

MORETTI et al., Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression, Endocrine-Related Cancer, 2003, pp. 161-67, Vol. 10, No. 2.

NECHUSHTAN et al., 1997 April 25, J. Biol. Chem., Vol. 272, No. 17, pp. 11597-603.

ROTE LISTE, 1997.

VAN GROENINGHEN et al., Effects of luteinising-hormone-releasing hormone on nervous-system tumours, The Lancet, August 1, 1998, pp. 372-73, Vol. 352, No. 9125.


Serial No.: 09/446,996

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicant hereby identifies the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2183.02-5641US
Serial No.: 10/327,621
Filing Date: 12/20/2002
Title: METHOD FOR RECOGNIZING AND DETERMINING GNRH RECEPTORS AND USE OF GNRH AGONIST FOR DECREASING THE REPLICATION OF MALIGNANT CELLS BEARING GNRH RECEPTORS OF TUMORS ORIGINATING IN THE NERVOUS SYSTEM AND/OR MENINGES AND/OR OF KAPOSI SARCOMA

This Supplemental Information Disclosure Statement is filed concurrent with the filing of a Request for Continued Examination. No fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: July 22, 2005
ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08
Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/446,996
Filing Date	December 30, 1999
First Named Inventor	Johannes C. van Groeninghen
Group Art Unit	1646
Examiner Name	J. Andres
Attorney Docket Number	2183.02-5649US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/446,996
Filing Date	December 30, 1999
First Named Inventor	Johannes C. van Groeninghen
Group Art Unit	1646
Examiner Name	J. Andres
Attorney Docket Number	2183 02-564911S

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HE et al., 1986, Clinical Chemistry, Vol. 32, No. 6, pp. 1159, abstract #542.	
		HOITINK et al., Stability of Gonadorelin and Relation Compounds, dissertation, U of Utrecht, 8/6/1998, CH. 1, p. 15, para. 2.	
		LAUE et al., Amer. J. of Diseases of Children, 1985, vol. 139, no. 11, pp. 1097-1100.	
		LIMONTA et al., The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans, Front, Neuroendocrinol. 203, pp. 279-95, Vol. 24.	
		MORETTI et al., Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells, J. of Clin. Endocrin. & Metab., 2002, pp. 3791-97, Vol. 87, No. 8.	
		MORETTI et al., Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression, Endocrine-Related Cancer, 2003, pp. 161-67, Vol. 10, No. 2.	
		NECHUSHTAN et al., 1997 April 25, J. Biol. Chem., Vol. 272, No. 17, pp. 11597-603.	
		ROTE LISTE, 1997.	
		VAN GROENINGHEN et al., Effects of luteinising-hormone-releasing hormone on nervous-system tumours, The Lancet, August 1, 1998, pp. 372-73, Vol. 352, No. 9125.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.